Benzodiazepines are disproportionately prescribed to older adults. Elderly adults with comorbid medical and psychiatric conditions, elderly adults taking multiple medications, and elderly women are the most likely adults to continuously use benzodiazepines. These are also the groups of elderly who are likely to experience adverse effects, including falls, accidents, and motor vehicle crashes. Despite recommendations for short-term treatment and the potential risks of long-term use, some patients continue to receive benefit for extended time periods, occasionally years. Future research needs to be directed at improved identification of which patients will benefit from intermittent versus continuous treatment while minimizing risk for adverse side effects. In order to advance the study of the risks and benefits of benzodiazepine use, we have proposed a set of definitions for classification of use. These definitions can be used to develop clinical guidelines based on empirically derived clinical research models.
Get full access to this article
View all access options for this article.
References
1.
1. Ballenger J.Benzodiazepines. In: Schatzberg AF, Nemeroff CB, Eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1998: 267–288.
2.
2. Pincus H, Tanielian M, Marcus S, et al. Prescribing trends in psychotropic medications: primary care, psychiatry and other medical specialities. JAMA1998; 279:526–531.
3.
3. Griffiths R, Weerts E.Benzodiazepine self-administration in humans and laboratory animals—implications for problem of long-term use and abuse. Psychopharmacology1997; 134:1–37.
6. Allgulander C, Lavori PW. Excess mortality among 3302 patients with “pure” anxiety neurosis. Arch Gen Psychiatry1991; 48:599–602.
7.
7. Kawachi I, Colditz G, Ascherio, et al. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation1994; 89:1992–1997.
8.
8. Kawachi I, Sparrow D, Vokonas P, et al. Symptoms of anxiety and risk of coronary heart disease. The Normative Study. Circulation1994; 90:2225–2229.
9.
9. Lindesay J.Phobic disorders in the elderly. Br J Psychiatry1991; 159:531–541.
10.
10. National Institutes of Health Consensus Development Conference Statement: the treatment of sleep disorders of older people. Sleep 1991; 14:169–177.
11.
11. Christensen D, Benfield W.Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc1998; 46:620–625.
12.
12. Small G, Rabins P, Barry P, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatric Society. JAMA1997; 278:1363–1371.
13.
13. Yodofsky S, Silver J, Hales R.Pharmacologic management of aggression in the elderly. J Clin Psychiatry1990; 51(Suppl): 22–28.
14.
14. Tariot P, Podgorske C, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry1993; 150:1063–1069.
15.
15. Rovner B, Kafonek S, Fillipp M, et al. Prevalence of mental illness in a community nursing home: another perspective. Am J Psychiatry1986; 143:1446–1449.
16.
16. Cohen-Mansfeld J, Billig N.Agitated behaviors in the elderly: a conceptual review. J Am Geriatr Soc1986; 34:711–721.
17.
17. Parker W.Effect of hospitalization on patient use of hypnotics. Am J Hosp Pharmacol1983; 40:446–467.
18.
18. Perry S, Wu A.Rationale for the use of hypnotic agents in a general hospital. Ann Intern Med1984; 100:441–446.
19.
19. Surendrakumar D, Dunn M, Roberts C.Hospital admission and the start of benzodiazepine use. BMJ1992; 304: 881.
20.
20. Grad R, Tamblyn R, Holbrook A, et al. Risk of a new benzodiazepine prescription in relation to recent hospitalization. J Am Geriatr Soc1999; 47:184–188.
21.
21. American Psychiatric Association Task Force report on benzodiazepine dependence, toxicity and abuse. Washington, DC: APA, 1990.
22.
22. Mellinger G, Baler M, Uhlenhuth E.Insomnia and its treatment. Arch Gen Psychiatry1985; 42:225–232.
23.
23. Balter M, Uhlenhuth E.New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry1992; 53(Suppl 12):34–39.
24.
24. Pinsker H, Suljaga-Petchel K.Use of benzodiazepines in primary-care geriatric patients. J Am Geriatr Soc1984; 32: 595–598.
25.
25. Umbert M, Fernandez J, Llorente M, et al. Prevalence and appropriateness of benzodiazepine use in frail, home-bound elderly. In: APA annual meeting new research abstracts. Washington, DC, 1999.
26.
26. Stewart R, Marks R, Padgett P, et al. Benzodiazepine use in an ambulatory elderly population: a 14-year overview. Clin Ther1994; 16:118–124.
27.
27. Mellinger G, Balter M, Uhlenhuth E.Prevalence and correlates of the long-term regular use of anxiolytics. JAMA1984; 251:375–379.
28.
28. Shader R, Greenblatt D.Use of benzodiazepines in anxiety disorders. N Engl J Med1993; 328:1398–1405.
29.
29. Nowell P, Mazumdar S, Buysse D, et al. Benzodiazepines and Zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA1997; 278:2170–2177.
30.
30. Rickels K, Case G, Downing T, et al. Long-term diazepam therapy and clinical outcome. JAMA1983; 250:767–771.
31.
31. Rodrigo E, King M, Williams P.Health of long-term benzodiazepine users. BMJ1988; 296:603–606.
32.
32. Morin C, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA1999; 281:991–999.
35. Griffiths R, Wolf B.Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol1990; 10:237–243.
36.
36. Zacny J, Galinkin J.Psychotropic drugs used in anesthesia practice: abuse liability and epidemiology of abuse. Anesthesiology1999; 90:269–284.
37.
37. de Wit H, Griffiths R.Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend1991; 28:83–111.
38.
38. de Wit H, Doty P.Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. Psychopharmacology1994; 115:529–538.
39.
39. Evans S, Griffiths R, deWit H. Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacology1996; 123:154–163.
40.
40. Chutuapa M, deWit H. Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis. Psychopharmacology1995; 121:91–103.
41.
41. Roache J, Stanley M, Creson D.Diazepam reinforcement in anxious patients. Exp Clin Psychopharmacol1996; 4:308–314.
42.
42. Woods J.Problems and opportunities in regulation of benzodiazepines. J Clin Pharmacol1998; 38:773–782.
43.
43. Frances A.Diagnostic and statistical manual of mental disorders.4th Ed.Washington, DC: American Psychiatric Press, 1994.
44.
44. Busto U, Romach M, Sellers E.Multiple drug use and psychiatric comorbidity in patients admitted with severe benzodiazepine dependence. J Clin Psychopharmacol1996; 16:51–57.
45.
45. Preston K, Griffiths R, Stitzer M, et al. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther1984; 36:534–541.
46.
46. Perera K, Jenner F.Some characteristics distinguishing high and low dose users of benzodiazepines. Br J Addiction1987; 82:1329–1334.
47.
47. Jinks M, Raschko R.A profile of alcohol and prescription drug abuse in a high-risk community-based elderly population. DICP1990; 24:971–975.
48.
48. Rifkin A, Doddi S, Karajgi B, et al. Benzodiazepine use and abuse by patients at outpatient clinics. Am J Psychiatry1989; 146:1331–1332.
49.
49. O'Hanlon J, Blaauw G, Riemersma J.Diazepam impairs lateral position control in highway driving. Science1982; 217:79–81.
50.
50. Ray W, Fought R, Decker M.Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol1992; 136:873–883.
51.
51. Neutel C.Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol1995; 5:239–244.
52.
52. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crashes in the elderly. JAMA1997; 278:27–31.
53.
53. Ray W.Safety and mobility of the older driver: a research challenge. JAMA1997; 278:66–67.
54.
54. World Health Organization.The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva: WHO, 1992.
55.
55. Linsen S, Breteler M, Zitman F.Defining benzodiazepine dependence: the confusion persists. Eur Psychiatry1995; 10:306–311.
56.
56. Kan C, Breteler M, Zitman F.High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand1997; 96:85–93.
57.
57. Holroyd S, Duryee J.Substance use disorders in a geriatric psychiatry outpatient clinic: prevalence and epidemiologic characteristics. J Nerv Ment Dis1997; 185:627–632.
58.
58. Whitcup M, Miller F.Unrecognized drug dependence in psychiatrically hospitalized elderly patients. J Am Geriatr Soc1987; 35:297–301.
59.
59. Martinez-Cano H, Ibanez MD, Vela-Bueno A, et al. DSM-III-R comorbidity in benzodiazepine dependence. Addiction1999; 94:97–107.
60.
60. Beekman A, deBeurs E, vanBalkom A, et al. Anxiety and depression in later life: co-occurrence and community of risk factors. Am J Psychiatry2000; 157:89–95.
61.
61. Llorente M, Eisdorfer C, Zarate Y, et al. Suicide among Hispanic elderly: Cuban-Americans in Dade County, Florida, 1990–1993. J Ment Health Aging1996; 2:79–87.
62.
62. Cohen D, Llorente M, Eisdorfer C.Homicide-suicide in older persons. Am J Psychiatry1998; 155:390–396.
63.
63. Martinez-Cano H, Vela-Bueno A, Ibanez MD, et al. Benzodiazepine types in high versus therapeutic dose dependence. Addiction1996; 91:1179–1186.
64.
64. De las Cuevas C, Sanz E, de la Fuente JA, et al. The severity of dependence scale (SDS) as a screening test for benzodiazepine dependence: SDS validation study. Addiction2000; 95:245–250.
65.
65. Greenblatt D, Harmatz J, Shader R.Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet1991; 212:165–177.
66.
66. Cook P, Flanagan R, James I.Diazepam tolerance: effect of age, regular sedation and alcohol. BMJ1984; 289:351–353.
67.
67. Hammerlein A, Derendorf H, Lowenthal D.Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet1998; 35:49–64.
68.
68. Forbes G, Reina J.Adult lean body mass declines with age: some longitudinal observations. Metabolism1970; 19:653–663.
69.
69. Campion E, deLabry L, Glynn R.The effect of age on serum albumin in healthy males: report from the normative aging study. J Gerontol1988; 43:M18–M20.
70.
70. Sotaniemi E, Arranto A, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther1996; 61:331–339.
71.
71. Greenblatt D, Divoll M, Abernethy D, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet1983; 8:233–253.
72.
72. Greenblatt D, Harmatz J, Shader R.Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). Clin Pharmacokinet1991; 21: 262–273.
73.
73. Greenblatt D, Preskorn S, Cotreau M, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther1992; 52:479–486.
74.
74. Ruffalo R, Thompson J.Effect of cimetidine on the clearance of benzodiazepines. N Engl J Med1980; 303:753–754.
75.
75. Ruffalo R, Thompson J, Segal J.Cimetidine-benzodiazepine drug interaction. Am J Hosp Pharmacol1981; 38:1365–1366.
76.
76. Rickels K, Schweizer E, Case W, et al. Long-term therapeutic use of benzodiazepines: I: effects of abrupt discontinuation. JAMA1990; 47:899–907.
77.
77. Schweizer E, Rickels K, Case W, et al. Long-term therapeutic use of benzodiazepines: II: effects of gradual taper. JAMA1990; 47:908–915.
78.
78. Tyrer P, Owen R, Dawling S.Gradual withdrawal of diazepam after long-term therapy. Lancet1983; 1:1402–1406.
79.
79. Busto U, Sellers E, Naranjo C, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med1986; 315:854–859.
80.
80. Petrovic M, Pevernagie D, Noortgate N, et al. A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality. Int J Geriatr Psychiatry1999; 14:754–760.
81.
81. Schweizer E, Case W, Rickels K.Benzodiazepine dependence and withdrawal in elderly patients. Am J Psychiatry1989; 146:529–531.
82.
82. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry1992; 7:89–93.
83.
83. Habraken H, Soenen K, Blondeel L, et al. Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research. Eur J Clin Pharmacol1997; 51:355–358.
84.
84. Olpe H, Steinmann M.Age-related decline in the activity of noradrenergic neurons of the rat locus ceruleus. Brain Res1982; 251:174–176.
85.
85. Harrington, C, Tompkins C, Curtis M, et al. Psychotropic drug use in long-term care facilities: a review of the literature. Gerontologist1992; 32:822–823.
86.
86. Beers M, Ouslander J, Fingold S, et al. Inappropriate medication prescribing in skilled-nursing faculties. Arch Intern Med1992; 117:684–689.
87.
87. Beers M, Fingold S, Ouslander J, et al. Characteristics and quality of prescribing by doctors practicing in nursing homes. J Am Geriatr Soc1993; 41:802–807.
88.
88. Aparasu R, Fliginger S.Inappropriate medication prescribing for the elderly by office-based physicians. Ann Pharmacother1997; 31:823–829.
89.
89. Stuck A, Beers M, Steiner A, et al. Inappropriate medication use in community residing in older persons. Arch Intern Med1994; 154:195–200.
90.
90. Willcox S, Himmelstein D, Woolhander S.Inappropriate drug prescribing for the community-dwelling elderly. JAMA1994; 272:292–296.
91.
91. Golden A, Preston R, Barnett S, et al. Inappropriate medication prescribing in homebound older adults. J Am Geriatr Soc1999; 47:948–953.
92.
92. Beers M.Explicit criteria determining potentially inappropriate medication use by the elderly. Arch Intern Med1997; 157:1531–1536.
94. Barry K, Oslin D, Blow F. Prevention and management of alcohol problems in older adults. New York: Springer, in press.
95.
95. World Health Organization.Drug information. Geneva: WHO, 1999.
96.
96. World Health Organization.Drug information. Geneva: WHO, 1998.
97.
97. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc1999; 47:30–39.
98.
98. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med1998; 13:243–250.
99.
99. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther1998; 64:684–692.
100.
100. Ried LD, Johnson RE, Gettman DA. Benzodiazepine exposure and functional status in older people. J Am Geriatr Soc1998; 46:71–76.
101.
101. Spore D, Mor V, Hiris J, et al. Psychotropic use among older residents of board and care facilities. J Am Geriatr Soc1995; 43:1403–1409.
102.
102. Semla TP, Cohen D, Paveza G, et al. Drug use patterns of persons with Alzheimer's disease and related disorders living in the community. J Am Geriatr Soc1993; 41:408–413.
103.
103. Mayer-Oakes SA, Kelman G, Beers MH, et al. Benzodiazepine use in older, community-dwelling southern Californians: prevalence and clinical correlates. Ann Pharmacother1993; 27:416–421.
104.
104. Swartz M, Landerman R, George LK, Melviller ML, et al. Benzodiazepine antianxiety agents: prevalence and correlates of use in a southern community. Am J Public Health1991; 81:592–596.
